Boothbay Fund Management, LLC Alnylam Pharmaceuticals, Inc. Call Options Transaction History

Boothbay Fund Management, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$143.31 - $247.0 $3.07 Million - $5.29 Million	21,400 Added 62.94%	55,400 $13.5 Million
Q1 2024 May 15, 2024	SELL	$146.51 - $198.2 $835,107 - $1.13 Million	-5,700 Reduced 14.36%	34,000 $5.08 Million
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $6.01 Million - $7.8 Million	39,700 New	39,700 $7.6 Million
Q3 2022 Nov 14, 2022	SELL	$138.54 - $232.0 $207,810 - $348,000	-1,500 Reduced 4.13%	34,800 $6.97 Million
Q2 2022 Aug 15, 2022	BUY	$120.42 - $169.29 $2.47 Million - $3.47 Million	20,500 Added 129.75%	36,300 $5.29 Million
Q1 2022 May 16, 2022	SELL	$127.18 - $173.91 $496,002 - $678,249	-3,900 Reduced 19.8%	15,800 $2.58 Million
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $303,164 - $397,651	1,900 Added 10.67%	19,700 $3.34 Million
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $712,950 - $872,466	-4,200 Reduced 19.09%	17,800 $3.36 Million
Q2 2021 Aug 16, 2021	BUY	$128.63 - $176.89 $2.83 Million - $3.89 Million	22,000 New	22,000 $3.73 Million

642

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.1B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.